Immunodermatology News

MILAN — Secukinumab was effective in improving the signs and symptoms of moderate to severe hidradenitis suppurativa in two phase 3 clinical trials.

MILAN — Higher doses of povorcitinib were more efficacious in the treatment of hidradenitis suppurativa compared with lower doses, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

Biologic therapies were not associated with an elevated risk for respiratory infections compared with placebo in a meta-analysis of patients being treated for hidradenitis suppurativa.

Strong clinical responses were observed in a small cohort of patients with hidradenitis suppurativa treated with the Janus kinase inhibitor upadacitinib, according to study findings.

Therapy using a 308 nm laser was effective in inducing long-term repigmentation of the face in pediatric vitiligo, particularly in facial lesions, according to researchers.

The FDA has approved the topical Janus kinase inhibitor Opzelura for the treatment of nonsegmental vitiligo in adolescents and adults, Incyte announced in a press release.

Patients with mucous membrane pemphigoid should be monitored by a multidisciplinary team due to a risk for malignancy, according to a study.

Results of a study showed that antirituximab antibodies are common among patients with pemphigus who have been treated with rituximab, according to data published in JAMA Dermatology.

Assessment of craniofacial morphea using 3D stereophotogrammetry correlated highly with assessments made using clinical evaluation, according to study findings.

CLEVELAND — In this video from the Medical Dermatology Therapy Update II meeting, Joseph C. English III, MD, professor of dermatology at the University of Pittsburgh, gives an update on sarcoidosis and granulomatous diseases.